Literature DB >> 3871825

Alteration of lymphocyte functions by 8-methoxypsoralen and longwave ultraviolet radiation. I. Suppressive effects of PUVA on T-lymphocyte migration in vitro.

H Okamoto, M Takigawa, T Horio.   

Abstract

We investigated the influence of 8-methoxypsoralen (8-MOP) plus long-wave ultraviolet radiation (PUVA) on lymphocyte migration in vitro. Nylon wool-purified, mouse splenic T lymphocytes showed locomotive responses to casein, normal mouse serum (NMS), and zymosan-activated mouse serum (ZAS). Migratory responses to casein and NMS, and to ZAS were remarkably suppressed in lymphocytes exposed to 0.5 J/cm2 UVA plus 0.1 micrograms/ml 8-MOP and to 0.8 J/cm2 UVA plus 8-MOP, respectively. The PUVA treatment used in the present study had no effect on random movement and lymphocyte viability. T lymphocytes cultured in the absence of mitogenic agent for 24 h demonstrated a greater increase in their migration activity than noncultured cells, while lymphocytes cultured after 1.0 J/cm2 PUVA pretreatment remained low. These findings suggest that the therapeutic effect of PUVA on inflammatory skin disorders may be due in part to the suppression of lymphocyte migration.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3871825     DOI: 10.1111/1523-1747.ep12265126

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  3 in total

1.  Ultraviolet radiation suppresses mouse-ear edema induced by topical application of arachidonic acid.

Authors:  K Danno; K Toda; K Ikai; T Horio; S Imamura
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

2.  Comparison of narrow-band UVB vs. psoralen with UVA phototherapy for early-stage mycosis fungoides.

Authors:  Amrita Goyal
Journal:  Ann Transl Med       Date:  2019-12

3.  Comparison of Narrowband UV-B With Psoralen-UV-A Phototherapy for Patients With Early-Stage Mycosis Fungoides: A Systematic Review and Meta-analysis.

Authors:  Kevin Phan; Vignesh Ramachandran; Hiva Fassihi; Deshan F Sebaratnam
Journal:  JAMA Dermatol       Date:  2019-03-01       Impact factor: 10.282

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.